<産業資料/調査レポートの題名> 2022年7月19日

自己免疫疾患治療薬の世界市場2018-2022


◆英文タイトル:Global Autoimmune Drugs Market 2018-2022

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 05: PIPELINE ANALYSIS
PART 06: MARKET SIZING
• Market definition
• Market sizing 2017
• Market size and forecast 2017-2022
PART 07: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 08: MARKET SEGMENTATION BY THERAPY AREA
• Segmentation by therapy area
• Comparison by therapy area
• Rheumatoid arthritis – Market size and forecast 2017-2022
• Multiple sclerosis – Market size and forecast 2017-2022
• Psoriasis – Market size and forecast 2017-2022
• Inflammatory bowel disease – Market size and forecast 2017-2022
• Others – Market size and forecast 2017-2022
• Market opportunity by therapy area
PART 09: MARKET SEGMENTATION BY TYPE OF MOLECULE
• Segmentation by type of molecule
• Biologics
• Small molecules
PART 10: CUSTOMER LANDSCAPE
PART 11: REGIONAL LANDSCAPE
• Geographical segmentation
• Regional comparison
• Americas – Market size and forecast 2017-2022
• EMEA – Market size and forecast 2017-2022
• APAC – Market size and forecast 2017-2022
• Market opportunity
PART 12: DECISION FRAMEWORK
PART 13: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 14: MARKET TRENDS
PART 15: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 16: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• AbbVie
• Amgen
• Johnson & Johnson
• Novartis
• Pfizer
• UCB
PART 17: APPENDIX
• List of abbreviations


Exhibit 01: Parent market
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: mAbs and biologics for autoimmune diseases
Exhibit 06: Small molecules for autoimmune diseases
Exhibit 07: Market definition – Inclusions and exclusions checklist
Exhibit 08: Market size 2017
Exhibit 09: Validation techniques employed for market sizing 2017
Exhibit 10: Global – Market size and forecast 2017-2022 ($ bn)
Exhibit 11: Biosimilars approved in 2017
Exhibit 12: Global – Year-over-year growth 2018-2022 (%)
Exhibit 13: Five forces analysis 2017
Exhibit 14: Five forces analysis 2022
Exhibit 15: Bargaining power of buyers
Exhibit 16: Bargaining power of suppliers
Exhibit 17: Threat of new entrants
Exhibit 18: Threat of substitutes
Exhibit 19: Threat of rivalry
Exhibit 20: Market condition – Five forces 2017
Exhibit 21: Therapy area – Market share 2017-2022 (%)
Exhibit 22: Comparison by therapy area
Exhibit 23: Rheumatoid arthritis – Market size and forecast 2017-2022 ($ bn)
Exhibit 24: Rheumatoid arthritis – Year-over-year growth 2018-2022 (%)
Exhibit 25: Multiple sclerosis – Market size and forecast 2017-2022 ($ bn)
Exhibit 26: Multiple sclerosis – Year-over-year growth 2018-2022 (%)
Exhibit 27: Psoriasis – Market size and forecast 2017-2022 ($ bn)
Exhibit 28: Psoriasis – Year over year growth 2018-2022 (%)
Exhibit 29: Inflammatory bowel disease – Market size and forecast 2017-2022 ($ bn)
Exhibit 30: Inflammatory bowel disease – Year-over-year growth 2018-2022 (%)
Exhibit 31: Others – Market size and forecast 2017-2022 ($ bn)
Exhibit 32: Others – Year-over-year growth 2018-2022 (%)
Exhibit 33: Market opportunity by therapy area
Exhibit 34: Customer landscape
Exhibit 35: Global – Market share by geography 2017-2022 (%)
Exhibit 36: Regional comparison
Exhibit 37: Americas – Market size and forecast 2017-2022 ($ bn)
Exhibit 38: Molecules in the pipeline for autoimmune disorders in the Americas
Exhibit 39: Americas – Year-over-year growth 2018-2022 (%)
Exhibit 40: Top 3 countries in Americas
Exhibit 41: EMEA – Market size and forecast 2017-2022 ($ bn)
Exhibit 42: EMEA – Year-over-year growth 2018-2022 (%)
Exhibit 43: Top 3 countries in EMEA
Exhibit 44: APAC – Market size and forecast 2017-2022 ($ bn)
Exhibit 45: APAC – Year-over-year growth 2018-2022 (%)
Exhibit 46: Top 3 countries in APAC
Exhibit 47: Market opportunity
Exhibit 48: Sales of major autoimmune drugs
Exhibit 49: Patent expiration dates for some of the biologics
Exhibit 50: Vendor landscape
Exhibit 51: Landscape disruption
Exhibit 52: Vendors covered
Exhibit 53: Vendor classification
Exhibit 54: Market positioning of vendors
Exhibit 55: AbbVie overview
Exhibit 56: AbbVie – Business segments
Exhibit 57: AbbVie – Organizational developments
Exhibit 58: AbbVie – Geographic focus
Exhibit 59: AbbVie – Key offerings
Exhibit 60: Amgen overview
Exhibit 61: Amgen – Business segments
Exhibit 62: Amgen – Organizational developments
Exhibit 63: Amgen – Geographic focus
Exhibit 64: Amgen – Key offerings
Exhibit 65: Johnson & Johnson overview
Exhibit 66: Johnson & Johnson – Business segments
Exhibit 67: Johnson & Johnson – Organizational developments
Exhibit 68: Johnson & Johnson – Geographic focus
Exhibit 69: Johnson & Johnson – Segment focus
Exhibit 70: Johnson & Johnson – Key offerings
Exhibit 71: Novartis overview
Exhibit 72: Novartis – Business segments
Exhibit 73: Novartis – Organizational developments
Exhibit 74: Novartis – Geographic focus
Exhibit 75: Novartis – Segment focus
Exhibit 76: Novartis – Key offerings
Exhibit 77: Pfizer overview
Exhibit 78: Pfizer – Business segments
Exhibit 79: Pfizer – Organizational developments
Exhibit 80: Pfizer – Geographic focus
Exhibit 81: Pfizer – Segment focus
Exhibit 82: Pfizer – Key offerings
Exhibit 83: UCB overview
Exhibit 84: UCB – Business segments
Exhibit 85: UCB – Organizational developments
Exhibit 86: UCB – Geographic focus
Exhibit 87: UCB – Segment focus
Exhibit 88: UCB – Key offerings



LINEで送る
Share on LinkedIn
このエントリーをはてなブックマークに追加
Bookmark this on BuzzURL
Bookmark this on Yahoo Bookmark